Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Tax Provisions (2022 - 2024)

Historic Tax Provisions for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q3 2024 value amounting to -$3.3 million.

  • Xeris Biopharma Holdings' Tax Provisions fell 88343.2% to -$3.3 million in Q3 2024 from the same period last year, while for Jun 2025 it was -$3.3 million, marking a year-over-year decrease of 78962.66%. This contributed to the annual value of -$2.3 million for FY2024, which is 8158.53% down from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Tax Provisions stood at -$3.3 million for Q3 2024, which was down 88343.2% from $749000.0 recorded in Q2 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Tax Provisions registered a high of $749000.0 during Q2 2024, and its lowest value of -$3.3 million during Q3 2024.
  • Its 3-year average for Tax Provisions is -$494100.0, with a median of -$338500.0 in 2022.
  • Over the last 5 years, Xeris Biopharma Holdings' Tax Provisions had its largest YoY gain of 21096.3% in 2024, and its largest YoY loss of 88343.2% in 2024.
  • Over the past 3 years, Xeris Biopharma Holdings' Tax Provisions (Quarter) stood at -$338000.0 in 2022, then surged by 30.18% to -$236000.0 in 2023, then plummeted by 1308.47% to -$3.3 million in 2024.
  • Its Tax Provisions stands at -$3.3 million for Q3 2024, versus $749000.0 for Q2 2024 and $307000.0 for Q1 2024.